Investigational antibody active against adult T-cell leukemia-lymphoma

Japanese researchers carried out a multicenter, Phase II study evaluating an investigational molecule in patients with relapsed adult T-cell leukemia-lymphoma (ATL), traditionally a very difficult T-cell subtype to treat and often resistant to conventional chemotherapy.

A total of 28 patients were enrolled. According to findings published in the Journal of Clinical Oncology, researchers determined that half of the patients with ATL responded to KW-0761, a humanized anti-CC chemokine receptor-4 monoclonal antibody.

Median progression free survival (PFS) was 5.2 months, and median overall survival (OS) was 13.7 months.

Researchers concluded that "further investigation is warranted."